Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

miRNA: the new frontier in cancer medicine.

Ju J, Jiang J, Fesler A.

Future Med Chem. 2013 Jun;5(9):983-5. doi: 10.4155/fmc.13.74. No abstract available.

2.

Roles of microRNAs in cancer stem cells.

Zhou N, Mo YY.

Front Biosci (Schol Ed). 2012 Jan 1;4:810-8. Review.

PMID:
22202092
3.

[Epithelial-mesenchymal transition and cancer stem cells].

Zou DD, Tang XB.

Zhonghua Bing Li Xue Za Zhi. 2013 Jan;42(1):62-5. doi: 10.3760/cma.j.issn.0529-5807.2013.01.018. Review. Chinese. No abstract available.

PMID:
23611281
4.

Review of miR-200b and cancer chemosensitivity.

Feng B, Wang R, Chen LB.

Biomed Pharmacother. 2012 Sep;66(6):397-402. doi: 10.1016/j.biopha.2012.06.002. Epub 2012 Jun 29. Review.

PMID:
22795796
5.

Function of miRNA in controlling drug resistance of human cancers.

Hong L, Yang Z, Ma J, Fan D.

Curr Drug Targets. 2013 Sep;14(10):1118-27. Review.

PMID:
23834156
6.

RNA inhibition, microRNAs, and new therapeutic agents for cancer treatment.

Spizzo R, Rushworth D, Guerrero M, Calin GA.

Clin Lymphoma Myeloma. 2009;9 Suppl 3:S313-8. doi: 10.3816/CLM.2009.s.030. Review.

PMID:
19778859
7.

Evaluation of non-coding RNAs as potential targets in head and neck squamous cell carcinoma cancer stem cells.

Rahimy E, Kuo SZ, Ongkeko WM.

Curr Drug Targets. 2014;15(13):1247-60. Review.

PMID:
25341422
8.

Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice.

Giovannetti E, Erozenci A, Smit J, Danesi R, Peters GJ.

Crit Rev Oncol Hematol. 2012 Feb;81(2):103-22. doi: 10.1016/j.critrevonc.2011.03.010. Epub 2011 May 5. Review.

PMID:
21546262
9.

Targeting a murky cancer reservoir: more researchers set their sights on cancer stem cells.

Nelson B.

Cancer Cytopathol. 2013 Feb;121(2):55-6. doi: 10.1002/cncy.21282. No abstract available.

10.

miRNAs modulate the drug response of tumor cells.

Wu X, Xiao H.

Sci China C Life Sci. 2009 Sep;52(9):797-801. doi: 10.1007/s11427-009-0114-4. Epub 2009 Oct 6. Review.

PMID:
19802736
11.

Can the chemotherapeutic agents perform anticancer activity through miRNA expression regulation? Proposing a new hypothesis [corrected].

Chakraborty C, Doss CG, Sarin R, Hsu MJ, Agoramoorthy G.

Protoplasma. 2015 Nov;252(6):1603-10. doi: 10.1007/s00709-015-0776-7. Epub 2015 Feb 20. Erratum in: Protoplasma. 2015 Nov;252(6):1611.

PMID:
25698235
12.

Emerging role of microRNAs to tackle drug resistance in pancreatic cancer.

Neesse A, Gress TM.

Gut. 2015 Dec;64(12):1842-3. doi: 10.1136/gutjnl-2015-309503. Epub 2015 Jun 3. No abstract available.

PMID:
26041749
13.

MicroRNAs in breast cancer initiation and progression.

Liu H.

Cell Mol Life Sci. 2012 Nov;69(21):3587-99. doi: 10.1007/s00018-012-1128-9. Epub 2012 Aug 28. Review.

14.

miRNAs highlights in stem and cancer cells.

Martignani E, Miretti S, Accornero P, Baratta M.

Mini Rev Med Chem. 2011 Nov;11(13):1165-82. Review.

15.

Editorial (hot topic: miRNAs as legitimate targets for cancer therapy).

Wang Z.

Curr Drug Targets. 2013 Sep;14(10):1093. No abstract available.

PMID:
23834143
16.

Targeting microRNAs in epithelial-to-mesenchymal transition-induced cancer stem cells: therapeutic approaches in cancer.

Garg M.

Expert Opin Ther Targets. 2015 Feb;19(2):285-97. doi: 10.1517/14728222.2014.975794. Epub 2015 Jan 7. Review.

PMID:
25563894
17.

Modulation of microRNAs for potential cancer therapeutics.

Wu W.

Methods Mol Biol. 2011;676:59-70. doi: 10.1007/978-1-60761-863-8_5.

PMID:
20931390
18.

Camptothecin resistance in cancer: insights into the molecular mechanisms of a DNA-damaging drug.

Beretta GL, Gatti L, Perego P, Zaffaroni N.

Curr Med Chem. 2013;20(12):1541-65. Review.

PMID:
23432590
19.

Hyaluronan-CD44 interaction promotes oncogenic signaling, microRNA functions, chemoresistance, and radiation resistance in cancer stem cells leading to tumor progression.

Bourguignon LY, Shiina M, Li JJ.

Adv Cancer Res. 2014;123:255-75. doi: 10.1016/B978-0-12-800092-2.00010-1. Review.

PMID:
25081533
20.

MicroRNAs and cancer: towards a personalized medicine.

Fabbri M.

Curr Mol Med. 2013 Jun;13(5):751-6. Review.

PMID:
23642056

Supplemental Content

Support Center